FTC Suit Against Cephalon’s Reverse Settlements Focuses On Side Deals

Agency claims that Cephalon's deals with four generic companies constitute unfair competition under the FTC Act.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet